ABBV-706

ABBV-706 is an antibody-drug conjugate developed by AbbVie. The sponsor describes its target as SEZ6 (seizure-related homolog 6), which OnCo does not yet have a target page for. The sponsor states: ABBV-706 is described as a targeted antibody-drug conjugate; a trial exclusion criterion barring prior SEZ6-targeted ADC use indicates it targets SEZ6, given intravenously in small cell lung cancer, alone or combined with atezolizumab. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07365241 (A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT07365241, plans to enrol 531 participants with primary completion expected 2030-09. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.